Previous 10 | Next 10 |
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, ...
2023-12-13 23:43:55 ET Summary X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixafor will likely still have a role in chronic neutro...
2023-12-12 15:25:46 ET More on X4 Pharmaceuticals X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript X4 Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation X4 Pharmaceuticals says CEO Paula Ragan sells 239.4K shares X4 shares ju...
Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to present additional CN Phase 2 clinical trial data in 1H 2024 BOSTON, Dec. 09, 2023 (GLOBE ...
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being ...
2023-11-09 12:37:01 ET X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer...
2023-11-09 06:06:07 ET More on X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market X4 Pharmaceuticals says CEO Paula Ragan sells 239.4K shares X4 shares jump as FDA accepts priority review of pediatric WHIM drug ...
U.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if approved Presentations of additional data from ongoing Phase 2 clinical trial of mavori...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-7.04% Change Percent:
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood , the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 ...
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing...
The FDA approved on Monday X4 Pharmaceuticals Inc’s (NASDAQ:XFOR) Xolremdi (mavorixafor) capsules for use in patients 12 years of age and ...